NRBO READ THE FULL NRBO RESEARCH REPORT Business Update Topline Results from Phase 2a Trial of DA-1241 in MASH Expected in ...
GemVax revealed Tuesday that its peptide drug candidate GV1001 missed the mark in a phase 2a study in progressive supranuclear palsy (PSP). PSP is a degenerative disease, not unlike Parkinson’s ...
"Completion of patient dosing in the Phase 2a clinical trial of DA-1241 ... Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a ...
"Completion of patient dosing in the Phase 2a clinical trial of DA-1241 ... Agonism of GPR119 in the gut promotes the release of key gut peptides GLP-1, GIP, and PYY. These peptides play a further ...
GemVax & KAEL Co., Ltd. ("GemVax"; KOSDAQ ticker: 082270) announced that topline results of a Phase 2a clinical trial (the "Phase 2a PSP Clinical Trial") of GV1001, an investigational peptide drug for ...
8d
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the third quarter ended ...
Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...
The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity ... programs have entered Phase 1/2a imaging and therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback